# Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

> **NCT05737485** · PHASE1 · COMPLETED · sponsor: **ReCode Therapeutics** · enrollment: 9 (actual)

## Conditions studied

- Primary Ciliary Dyskinesia

## Interventions

- **DRUG:** RCT1100

## Key facts

- **NCT ID:** NCT05737485
- **Lead sponsor:** ReCode Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-18
- **Primary completion:** 2024-07-25
- **Final completion:** 2025-01-13
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737485, "Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05737485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*